
## Hans-Peter Schmid

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1385802/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer, 1993, 71, 933-938.	4.1	478
2	Youssef's Syndrome: Preservation of Uterine Function with Subsequent Successful Pregnancy following Surgical Repair. Urologia Internationalis, 1994, 52, 220-222.	1.3	396
3	Prevention and early detection of prostate cancer. Lancet Oncology, The, 2014, 15, e484-e492.	10.7	372
4	Observations on the doubling time of prostate cancer.The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer, 1993, 71, 2031-2040.	4.1	356
5	Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ: British Medical Journal, 2018, 361, k2338.	2.3	210
6	Biological Variation of Total Prostate-Specific Antigen: A Survey of Published Estimates and Consequences for Clinical Practice. Clinical Chemistry, 2005, 51, 1342-1351.	3.2	131
7	Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunology, Immunotherapy, 2006, 55, 1524-1533.	4.2	104
8	An Abbreviated Standard Procedure for Accurate Tumor Volume Estimation in Prostate Cancer. American Journal of Surgical Pathology, 1992, 16, 184-191.	3.7	96
9	Prostatic Artery Embolization versus Standard Surgical Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. European Urology Focus, 2019, 5, 1091-1100.	3.1	80
10	Serum free prostate specific antigen: Isoenzymes in benign hyperplasia and cancer of the prostate. Prostate, 1995, 27, 212-219.	2.3	65
11	Prostatic Artery Embolisation Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: 2-yr Outcomes of a Randomised, Open-label, Single-centre Trial. European Urology, 2021, 80, 34-42.	1.9	64
12	Update on screening for prostate cancer with prostate-specific antigen. Critical Reviews in Oncology/Hematology, 2004, 50, 71-78.	4.4	52
13	Prevention and treatment of symptoms associated with indwelling ureteral stents: A systematic review. International Journal of Urology, 2017, 24, 250-259.	1.0	52
14	Therapeutic options for intractable hematuria in advanced bladder cancer. International Journal of Urology, 2013, 20, 651-660.	1.0	50
15	Outcome prediction of prostatic artery embolization: <i>post hoc</i> analysis of a randomized, openâ€label, nonâ€inferiority trial. BJU International, 2019, 124, 134-144.	2.5	45
16	Information on surgical treatment of benign prostatic hyperplasia on YouTube is highly biased and misleading. BJU International, 2020, 125, 595-601.	2.5	44
17	Five meters of H2O: The pressure at the urinary bladder neck during human ejaculation. Prostate, 2000, 44, 339-341.	2.3	40
18	Economic Aspects of Morbidity Caused by Ureteral Stents. Urologia Internationalis, 2016, 97, 91-97.	1.3	37

#	Article	IF	CITATIONS
19	Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12ÂPatients. Journal of Vascular and Interventional Radiology, 2018, 29, 589-597.	0.5	36
20	In vivo and in vitro complex formation of prostate specific antigen with αi-anti-chymotrypsin. Prostate, 1995, 27, 166-175.	2.3	32
21	Semi-Quantitative Immunochromatographic Test for Prostate Specific Antigen in Whole Blood: Tossing the Coin to Predict Prostate Cancer?. European Urology, 2003, 43, 478-484.	1.9	31
22	Bicycle riding has no important impact on total and free prostate-specific antigen serum levels in older men. Urology, 2003, 61, 1177-1180.	1.0	25
23	Influence of patient education on morbidity caused by ureteral stents. International Journal of Urology, 2015, 22, 679-683.	1.0	24
24	Readability assessment of online patient education materials provided by the European Association of Urology. International Urology and Nephrology, 2017, 49, 2111-2117.	1.4	23
25	Impact of Minimal Lymph Node Metastasis on Long-Term Prognosis after Radical Prostatectomy. European Urology, 1997, 31, 11-16.	1.9	22
26	Prostate Biopsy in Central Europe: Results of a Survey of Indication, Patient Preparation and Biopsy Technique. Urologia Internationalis, 2007, 79, 60-66.	1.3	22
27	Bipolar versus Monopolar Transurethral Resection of the Prostate: Results of a Comparative, Prospective Bicenter Study – Perioperative Outcome and Long-Term Efficacy. Urologia Internationalis, 2013, 90, 62-67.	1.3	22
28	Prostate Specific Antigen Doubling Time as Auxiliary End Point in Hormone Refractory Prostatic Carcinoma. European Urology, 2003, 43, 28-30.	1.9	21
29	Inâ€hospital cost analysis of prostatic artery embolization compared with transurethral resection of the prostate: <i>post hoc</i> analysis of a randomized controlled trial. BJU International, 2019, 123, 1055-1060.	2.5	21
30	Active Monitoring (Deferred Treatment or Watchful Waiting) in the Treatment of Prostate Cancer. European Urology, 2001, 40, 488-494.	1.9	19
31	Radiation Exposure During Prostatic Artery Embolisation: A Systematic Review and Calculation of Associated Risks. European Urology Focus, 2021, 7, 608-611.	3.1	19
32	Late Recurrence of Adenoid Cystic Carcinoma of the Prostate. Scandinavian Journal of Urology and Nephrology, 2002, 36, 158-159.	1.4	18
33	Health-Related Quality of Life after Radical Prostatectomy and Low-Dose-Rate Brachytherapy for Localized Prostate Cancer. Urologia Internationalis, 2009, 82, 17-23.	1.3	18
34	Ejaculatory disorders after prostatic artery embolization: a reassessment of two prospective clinical trials. World Journal of Urology, 2020, 38, 2595-2599.	2.2	18
35	The rise and fall of PSA: clinical implications of prostate specific antigen kinetics. Urological Research, 2002, 30, 85-88.	1.5	16
36	Systematic assessment of information about surgical urinary stone treatment on YouTube. World Journal of Urology, 2021, 39, 935-942.	2.2	16

#	Article	IF	CITATIONS
37	Reduction of stentâ€associated morbidity by minimizing stent material: a prospective, randomized, singleâ€blind superiority trial assessing a customized †suture stent'. BJU International, 2021, 127, 596-605.	2.5	16
38	Information needs of early-stage prostate cancer patients: within- and between-group agreement of patients and health professionals. Supportive Care in Cancer, 2014, 22, 999-1007.	2.2	15
39	Nutrition, dietary supplements and adenocarcinoma of the prostate. Maturitas, 2011, 70, 339-342.	2.4	14
40	Multidisciplinary care in patients with prostate cancer: room for improvement. Supportive Care in Cancer, 2013, 21, 2327-2333.	2.2	13
41	Longitudinal Evaluation of Prostate-Specific Antigen Levels in a Case-Control Study. European Urology, 1997, 31, 127-127.	1.9	12
42	Combining Free and Total Prostate Specific Antigen Assays from Different Manufacturers: The Pitfalls. European Urology, 2002, 42, 577-582.	1.9	12
43	The European Association of Urology (EAU) Guidelines Methodology: A Critical Evaluation. European Urology, 2009, 56, 859-864.	1.9	12
44	The German linguistic validation of the Ureteral Stent Symptoms Questionnaire (USSQ). World Journal of Urology, 2017, 35, 443-447.	2.2	12
45	Testicular sarcoidosis. Urology Case Reports, 2018, 17, 109-110.	0.3	12
46	Symptoms Associated With Long-term Double-J Ureteral Stenting and Influence of Biofilms. Urology, 2019, 134, 72-78.	1.0	12
47	Adherence to European Association of Urology and National Comprehensive Cancer Network Guidelines Criteria for Inguinal and Pelvic Lymph Node Dissection in Penile Cancer Patients—A Survey Assessment in German-speaking Countries on Behalf of the European Prospective Penile Cancer Study Group. European Urology Focus, 2021, 7, 843-849.	3.1	12
48	Submucosal endocervicosis of the bladder: An ectopic, glandular structure of Müllerian origin. Scandinavian Journal of Urology and Nephrology, 2008, 42, 88-90.	1.4	11
49	Readability Assessment of Patient Education Material Published by German-Speaking Associations of Urology. Urologia Internationalis, 2018, 100, 79-84.	1.3	11
50	Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus ( <scp>HIV</scp> )â€protease inhibitors lopinavir or nelfinavir. BJU International, 2018, 121, 600-609.	2.5	11
51	Improving Patient Education Materials: A Practical Algorithm from Development to Validation. Current Urology, 2019, 13, 64-69.	0.6	11
52	Clinical and Pathological Features of Highly Malignant Prostatic Carcinomas with Metastases to the Penis. Urologia Internationalis, 1994, 53, 135-138.	1.3	10
53	Predictive Value of Radiological Criteria for Disintegration Rates of Extracorporeal Shock Wave Lithotripsy. Urologia Internationalis, 2001, 66, 127-130.	1.3	10
54	Exposure of Treating Physician to Radiation during Prostate Brachytherapy Using Iodine-125 Seeds. Strahlentherapie Und Onkologie, 2009, 185, 689-695.	2.0	10

#	Article	IF	CITATIONS
55	Ciprofloxacin and Epirubicin Synergistically Induce Apoptosis in Human Urothelial Cancer Cell Lines. Urologia Internationalis, 2012, 88, 343-349.	1.3	10
56	Late seed migration after prostate brachytherapy with Iod-125 permanent implants. Prostate International, 2018, 6, 66-70.	2.3	10
57	Readability assessment of commonly used urological questionnaires. Investigative and Clinical Urology, 2018, 59, 297.	2.0	10
58	Predictability and Inducibility of Detachment of Prostatic Central Gland Tissue after Prostatic Artery Embolization: Post Hoc Analysis of a Randomized Controlled Trial. Journal of Vascular and Interventional Radiology, 2019, 30, 217-224.	0.5	10
59	Diagnosis of Prostate Cancer—The Clinical Use of Prostate Specific Antigen. EAU Update Series, 2003, 1, 3-8.	0.5	9
60	Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation. Prostate, 2005, 64, 323-331.	2.3	9
61	Feasibility of early intravesical instillation chemotherapy after transurethral resection of the bladder: A prospective evaluation in a consecutive series of 210 cases. Scandinavian Journal of Urology and Nephrology, 2008, 42, 522-527.	1.4	9
62	Prostatic Metastasis of Renal Cell Carcinoma Successfully Treated with Sunitinib. Urologia Internationalis, 2009, 83, 122-124.	1.3	9
63	PSA bounce after 125I-brachytherapy for prostate cancer as a favorable prognosticator. Strahlentherapie Und Onkologie, 2015, 191, 787-791.	2.0	9
64	Influence of biofilms on morbidity associated with short-term indwelling ureteral stents: a prospective observational study. World Journal of Urology, 2019, 37, 1703-1711.	2.2	9
65	Reasons to consider prostatic artery embolization. World Journal of Urology, 2021, 39, 2301-2306.	2.2	9
66	Identifying classes of the pain, fatigue, and depression symptom cluster in long-term prostate cancer survivors—results from the multi-regional Prostate Cancer Survivorship Study in Switzerland (PROCAS). Supportive Care in Cancer, 2021, 29, 6259-6269.	2.2	9
67	Radiotherapy or Surgery? Comparative, Qualitative Assessment of Online Patient Education Materials on Prostate Cancer. Current Oncology, 2021, 28, 3420-3429.	2.2	9
68	Prostate biopsy in Switzerland: A representative survey on how Swiss urologists do it. Scandinavian Journal of Urology and Nephrology, 2008, 42, 18-23.	1.4	8
69	High incidence of independent second malignancies after non-muscle-invasive bladder cancer. Scandinavian Journal of Urology and Nephrology, 2011, 45, 245-250.	1.4	8
70	Growth Hormone Inhibitors in Prostate Cancer: A Systematic Analysis. Urologia Internationalis, 2008, 81, 17-22.	1.3	7
71	CT-calculometry (CT-CM): advanced NCCT post-processing to investigate urinary calculi. World Journal of Urology, 2018, 36, 117-123.	2.2	7
72	Informative value of histological assessment of tissue acquired during aquablation of the prostate. World Journal of Urology, 2021, 39, 2043-2047.	2.2	7

#	Article	IF	CITATIONS
73	Longâ€ŧerm oncological and functional followâ€up in lowâ€doseâ€rate brachytherapy for prostate cancer: results from the prospective nationwide Swiss registry. BJU International, 2020, 125, 827-835.	2.5	7
74	Does the Identification of a Minimum Number of Cases Correlate With Better Adherence to International Guidelines Regarding the Treatment of Penile Cancer? Survey Results of the European PROspective Penile Cancer Study (E-PROPS). Frontiers in Oncology, 2021, 11, 759362.	2.8	7
75	Proposal for a standardized PSA doubling-time calculation. Anticancer Research, 2010, 30, 1633-6.	1.1	7
76	Absorption of Irrigation Fluid During Thulium Laser Vaporization of the Prostate. Journal of Endourology, 2017, 31, 380-383.	2.1	6
77	Recurrent Dystrophic Calcification of the Prostatic Resection Cavity After Transurethral Resection of the Prostate: Clinical Presentation and Endoscopic Management. Journal of Endourology Case Reports, 2017, 3, 81-83.	0.3	6
78	Spoilt for Choice: A Survey of Current Practices of Surgical Urinary Stone Treatment and Adherence to Evidence-Based Guidelines among Swiss Urologists. Urologia Internationalis, 2019, 103, 357-363.	1.3	6
79	Healthâ€related quality of life in longâ€ŧerm prostate cancer survivors after nerveâ€sparing and nonâ€nerveâ€sparing radical prostatectomy—Results from the multiregional PROCAS study. Cancer Medicine, 2020, 9, 5416-5424.	2.8	6
80	Prostate-Specific Antigen Doubling Time: A Potential Surrogate End Point in Hormone-Refractory Prostate Cancer. Journal of Clinical Oncology, 1999, 17, 1644c-1644c.	1.6	5
81	Operative Therapy in Disease Progression and Local Recurrence of Renal Cell Carcinoma. Urologia Internationalis, 1999, 63, 10-15.	1.3	5
82	Rising Prostate-Specific Antigen after Primary Treatment of Prostate Cancer: Sequential Hormone Manipulation. Urologia Internationalis, 2007, 79, 95-104.	1.3	5
83	Qualitative Assessment of Medical Information on YouTube: A Multilingual Comparison of Common Urological Conditions. Urologia Internationalis, 2021, 105, 757-763.	1.3	5
84	Prediction of Bacteriuria Based on Clinical or Laboratory Parameters in Patients with Indwelling Ureteral Stents Before Ureterorenoscopy Should Not Substitute for Urine Cultures. Journal of Endourology, 2018, 32, 739-745.	2.1	4
85	Prostatic Artery Embolisation: Do We Still Need It and for Whom?. European Urology Focus, 2022, 8, 384-387.	3.1	4
86	Hormonal Therapy of Prostate Cancer: Is There Any News?. Urologia Internationalis, 1999, 63, 80-85.	1.3	3
87	Consecutive Spontaneous Rupture of the Lower Pole Renal Artery and Main Renal Artery Due to Type 1 Neurofibromatosis. Urology, 2011, 77, 1339-1340.	1.0	3
88	Ectopic Adrenocortical Tissue in the Spermatic Cord in a 44-Year-old Man. Urology Case Reports, 2014, 2, 169-170.	0.3	3
89	Life-Threatening Bleeding from Peristomal Varices after Cystoprostatectomy: Multimodal Approach in a Cirrhotic, Encephalopathic Patient with Severe Portal Hypertension. Case Reports in Urology, 2015, 2015, 1-3.	0.3	3
90	Detection of microbial colonization of the urinary tract of patients prior to secondary ureterorenoscopy is highly variable between different types of assessment: results of a prospective observational study. Biofouling, 2019, 35, 1083-1092.	2.2	3

#	Article	IF	CITATIONS
91	Aquablation versus holmium laser enucleation of the prostate in the treatment of benign prostatic hyperplasia in medium-to-large-sized prostates (ATHLETE): protocol of a prospective randomised trial. BMJ Open, 2021, 11, e046973.	1.9	3
92	Extension of the therapeutic spectrum in castration-resistant prostate cancer: Osteoclast inhibition with denosumab. Translational Andrology and Urology, 2012, 1, 118-9.	1.4	3
93	Accurate Control of the Superficial and Deep Dorsal Veins during Radical Retropubic Prostatectomy: The Münster Clamp Technique. Urologia Internationalis, 2003, 70, 151-153.	1.3	2
94	Spontaneous Priapism after Radical Retropubic Prostatectomy. Urologia Internationalis, 2006, 77, 182-183.	1.3	1
95	Intermittent Ureteral Herniation – Rare Cause of Flank Pain. Urologia Internationalis, 2006, 77, 286-288.	1.3	1
96	Re: Selective Inhibition of CYP17 with Abiraterone Acetate is Highly Active in the Treatment of Castration-Resistant Prostate Cancer. European Urology, 2009, 56, 744-745.	1.9	1
97	Re: Clinicopathological Features and Prognostic Value of Incidental Prostatic Adenocarcinoma in Radical Cystoprostatectomy Specimens: A Systematic Review and Meta-analysis of 13 140 Patients. European Urology, 2017, 72, 154-155.	1.9	1
98	First Report of a Symptomatic Calculus of the Ampulla of the Ductus Deferens. Journal of Endourology Case Reports, 2020, 6, 253-255.	0.3	1
99	Stay cool! Special underwear for cyclic cooling significantly decreases scrotal skin temperature. Central European Journal of Urology, 2021, 74, 468-470.	0.3	1
100	Safety of Magnetic Resonance Imaging in patients under Sacral Neuromodulation with an InterStim Neuromodulator. Urology, 2021, 154, 115-119.	1.0	1
101	In-hospital cost analysis of aquablation compared with transurethral resection of the prostate in the treatment of benign prostatic enlargement. Swiss Medical Weekly, 2022, 152, w30136.	1.6	1
102	Re: Vaccination of Hormone-Refractory Prostate Cancer Patients with Peptide Cocktail-Loaded Dendritic Cells: Results of a Phase 1 Clinical Trial. European Urology, 2007, 51, 853-854.	1.9	0
103	Hereditary persistence of alpha-fetoprotein mimicking testicular cancer in a patient with acute epididymitis. Scandinavian Journal of Urology and Nephrology, 2011, 45, 354-355.	1.4	0
104	First Report on Joint Use of a Da Vinci® Surgical System with Transfer of Surgical Know-How between Two Public Hospitals. Urologia Internationalis, 2014, 93, 1-9.	1.3	0
105	Re: Refractory Chronic Pelvic Pain Syndrome in Men: Can Transcutaneous Electrical Nerve Stimulation Help?. European Urology, 2014, 65, 669-670.	1.9	0
106	Readability Assessment of Commonly Used German Urological Questionnaires. Current Urology, 2019, 13, 87-93.	0.6	0
107	Initial Diagnosis and Detection of Very Late Local Recurrence of a Ductal Prostate Cancer due to a Ureteral Stone. Case Reports in Urology, 2020, 2020, 1-4.	0.3	0
108	Re: Early Results of Unilateral Prostatic Artery Embolization as a Focal Therapy in Patients with Prostate Cancer Under Active Surveillance: Cancer Prostate Embolisation, a Pilot Study. European Urology, 2021, 81, 121-121.	1.9	0

#	Article	IF	CITATIONS
109	Urinary Stone Location with Ureteral Stents in Place: Always on the Move, and not Where you Would Expect. Urology Journal, 2020, 17, 667-670.	0.4	Ο